TY - JOUR
T1 - Outcome in breast molecular subtypes according to nodal status and surgical procedures
AU - Mazouni, Chafika
AU - Rimareix, Françoise
AU - Mathieu, Marie Christine
AU - Uzan, Catherine
AU - Bourgier, Céline
AU - André, Fabrice
AU - Delaloge, Suzette
AU - Garbay, Jean Rémi
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Background: The purpose of our study was to evaluate the surgical treatment and outcome of breast cancer according to molecular subtypes. Methods: We identified 1,194 patients consecutively treated for primary breast cancer from 2004 to 2010. The type of surgery, pathological findings, local recurrence, and distant metastasis were evaluated for 5 molecular subtypes: luminal A and B, luminal HER2 (Human Epidermal Growth Factor Receptor 2), HER2, and triple negative. Results: Breast-conserving surgery (BCS) was performed more frequently in luminal A (70.6%), triple-negative (66.2%), and luminal HER2 tumors (60.9%) (P <.001). A sentinel node biopsy was performed more frequently in luminal A (60%), and luminal HER2 (29.3%) types (P <.001). Among the 791 BCS, positive nodes were observed more often in HER2 (50%) and luminal B (44.9%) types (P = .0003). The number of local recurrences was higher in the node-negative luminal B subtype (3.4%). Conclusions: Molecular subtypes exert an impact on BCS and nodal surgery rates. The local relapse rates are influenced by the molecular subtypes according to the nodal status.
AB - Background: The purpose of our study was to evaluate the surgical treatment and outcome of breast cancer according to molecular subtypes. Methods: We identified 1,194 patients consecutively treated for primary breast cancer from 2004 to 2010. The type of surgery, pathological findings, local recurrence, and distant metastasis were evaluated for 5 molecular subtypes: luminal A and B, luminal HER2 (Human Epidermal Growth Factor Receptor 2), HER2, and triple negative. Results: Breast-conserving surgery (BCS) was performed more frequently in luminal A (70.6%), triple-negative (66.2%), and luminal HER2 tumors (60.9%) (P <.001). A sentinel node biopsy was performed more frequently in luminal A (60%), and luminal HER2 (29.3%) types (P <.001). Among the 791 BCS, positive nodes were observed more often in HER2 (50%) and luminal B (44.9%) types (P = .0003). The number of local recurrences was higher in the node-negative luminal B subtype (3.4%). Conclusions: Molecular subtypes exert an impact on BCS and nodal surgery rates. The local relapse rates are influenced by the molecular subtypes according to the nodal status.
KW - Breast cancer
KW - Luminal B
KW - Molecular subtype
KW - Triple negative
UR - http://www.scopus.com/inward/record.url?scp=84877810317&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2012.06.006
DO - 10.1016/j.amjsurg.2012.06.006
M3 - Article
C2 - 23312273
AN - SCOPUS:84877810317
SN - 0002-9610
VL - 205
SP - 662
EP - 667
JO - American Journal of Surgery
JF - American Journal of Surgery
IS - 6
ER -